ES2686968T3 - Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas - Google Patents

Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas Download PDF

Info

Publication number
ES2686968T3
ES2686968T3 ES14795356.6T ES14795356T ES2686968T3 ES 2686968 T3 ES2686968 T3 ES 2686968T3 ES 14795356 T ES14795356 T ES 14795356T ES 2686968 T3 ES2686968 T3 ES 2686968T3
Authority
ES
Spain
Prior art keywords
leu
gly
wing
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14795356.6T
Other languages
English (en)
Spanish (es)
Inventor
Shuzhen Wang
Yijun Chen
Dongyang HE
Nan Liu
Chao Ma
Zhenyue GAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201310162738.3A external-priority patent/CN103214584B/zh
Priority claimed from CN201310163407.1A external-priority patent/CN103232543B/zh
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Application granted granted Critical
Publication of ES2686968T3 publication Critical patent/ES2686968T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES14795356.6T 2013-05-06 2014-05-05 Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas Active ES2686968T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201310162738.3A CN103214584B (zh) 2013-05-06 2013-05-06 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
CN201310163407.1A CN103232543B (zh) 2013-05-06 2013-05-06 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
CN201310162738 2013-05-06
CN201310163407 2013-05-06
PCT/CN2014/076768 WO2014180288A1 (zh) 2013-05-06 2014-05-05 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用

Publications (1)

Publication Number Publication Date
ES2686968T3 true ES2686968T3 (es) 2018-10-23

Family

ID=51866722

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14795356.6T Active ES2686968T3 (es) 2013-05-06 2014-05-05 Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas

Country Status (6)

Country Link
US (1) US10875903B2 (enExample)
EP (1) EP2995626B1 (enExample)
JP (1) JP2016520053A (enExample)
DK (1) DK2995626T3 (enExample)
ES (1) ES2686968T3 (enExample)
WO (1) WO2014180288A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112019007267A2 (pt) * 2016-12-20 2019-07-09 Hoffmann La Roche anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
RU2769769C2 (ru) 2017-01-05 2022-04-05 Кахр Медикал Лтд. СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
LT3565579T (lt) 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
KR20210044221A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
CN116640226B (zh) * 2022-04-02 2024-04-26 广东东阳光药业股份有限公司 一种抑制宿主抗外源免疫细胞hvg反应的嵌合受体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1705248A1 (en) * 1997-10-01 2006-09-27 G.D. Searle LLC. Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment
EP1086129A1 (en) * 1998-06-17 2001-03-28 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and methods of use thereof
EP1501861A4 (en) * 2002-05-06 2007-06-20 Univ Texas TARGETED BINDING PROTEINS FOR THE ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC REAGENTS
CA2575441A1 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers
WO2009086132A2 (en) * 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
CN101265482A (zh) * 2008-04-25 2008-09-17 罗以勤 重组肿瘤抑素-肿瘤坏死因子分泌型真核表达载体及其制备方法和用途
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
EP3670536A3 (en) 2011-04-01 2020-10-07 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
AU2012296588B2 (en) * 2011-08-17 2017-07-27 The Regents Of The University Of Colorado, A Body Corporate Transferrin-tumstatin fusion protein and methods for producing and using the same
CN103232543B (zh) * 2013-05-06 2014-12-03 中国药科大学 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
CN103214584B (zh) * 2013-05-06 2014-07-09 中国药科大学 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用

Also Published As

Publication number Publication date
JP2016520053A (ja) 2016-07-11
US20200062818A1 (en) 2020-02-27
DK2995626T3 (en) 2018-10-29
EP2995626A1 (en) 2016-03-16
EP2995626A4 (en) 2016-11-09
EP2995626B1 (en) 2018-07-11
US10875903B2 (en) 2020-12-29
WO2014180288A1 (zh) 2014-11-13

Similar Documents

Publication Publication Date Title
ES2686968T3 (es) Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas
US20200246420A1 (en) pHLIP® peptide-mediated epitope tethering at cell surfaces
CN102153653B (zh) 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
CN103237808B (zh) 抗癌融合蛋白
WO2013000234A1 (en) A novel recomnimant bifunctional fusion protein and its preparation and use
CN101717449B (zh) 重组TRAIL-Fc融合蛋白及其制备和应用
JP2022528030A (ja) 多機能性融合タンパク質及びその使用
CN106279423B (zh) Slit2D2-HSA融合蛋白及其在抗肿瘤中的应用
CN104974262B (zh) 重组双功能融合蛋白及其制法和用途
JPH03500415A (ja) インターロイキン２類似体
CN109810946A (zh) 天花粉蛋白用于致敏和/激活树突状细胞中的应用
CN102671185A (zh) 少棘蜈蚣多肽毒素omega-SLPTX-Ssm1a的应用
CN101698852B (zh) 具有cd137l功能的蛋白或多肽及其基因和应用
CN103232543B (zh) 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
CN110551205B (zh) 可溶性人肿瘤坏死因子凋亡相关诱导配体的突变体及其制备方法和应用
CN106674353B (zh) 一种新的天花粉融合蛋白及其应用
CN101456913A (zh) 一种抗肿瘤融合蛋白及其应用
KR101651330B1 (ko) 세포투과성이 우수한 ｔａｔ－ａ２０ 융합단백질의 제조방법 및 이의 용도
CN103214584B (zh) 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
CN109331177A (zh) 一种免疫增强型多价疫苗及其制备方法和应用
CN103937808B (zh) 一种重组家蚕素的表达方法及其抗肿瘤应用
CN115894706A (zh) 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用
JPH1189582A (ja) 炎症性サイトカイン誘導因子の遺伝子
CN117529496A (zh) 小分子调控的细胞信号传导表达系统
KR20130011056A (ko) 염증표적 수용체 및 염증 질환 치료용 약물 운반체